Assuming that the process is now validated and if there have been no changes between those development batches and what you validated, then that would make perfect sense. If you have changed the process, or if you have not yet validated the API process then, while Q7A doesn’t prohibit it, you’re putting a lot of drug product dollars on validating something that you have not yet shown to be consistent.
